Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Emory University
With
PRIMARY OBJECTIVE: I. Determine the recommended phase II dose for the combination of spartalizumab and siltuximab. SECONDARY OBJECTIVES: I. Define the toxicity profile of the combination of the recommended phase II dose of spartalizumab and siltuximab. II. Evaluate the activity of the combination of spartalizumab and siltuximab in previously treated patients with pancreatic cancer. EXPLORATORY OBJECTIVE: I. Evaluate the effect of the combination on the immune profile in the serum and in tumor biopsies. OUTLINE: This is a dose-escalation study of siltuximab. Participants receive spartalizumab intravenously (IV) over 30 minutes on day 1 and siltuximab IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, participants are followed up at 30, 60, 90, 120, and 150 days, then every 12 weeks thereafter.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted